CelLBxHealth (LSE:CLBX) has signed a new Statement of Work worth about US$65,000 with an unnamed US-based pharmaceutical company. The work involves processing around 100 patient samples on the company's Parsortix platform.

What was announced

On 14 October 2026, CelLBxHealth said it had signed a new Statement of Work (SOW) under an existing Master Services Agreement with a US-based pharmaceutical company. The customer was not named but was described as an "established" pharmaceutical partner, which indicates that this is follow-on business with an existing client rather than a new relationship.

The SOW is valued at approximately US$65,000. The company did not state the duration of the work or the expected delivery dates.

Scope of the work

Under the SOW, CelLBxHealth will process about 100 patient samples to isolate and harvest circulating tumour cells (CTCs). The harvested cells will then be used for downstream molecular analysis, including mRNA analysis.

The work will be carried out using the company's proprietary Parsortix platform, which CelLBxHealth describes as a label-free microfluidic system. Circulating tumour cells are cancer cells that have shed from a tumour into the bloodstream. A label-free approach separates cells on the basis of physical characteristics rather than by tagging them with antibodies or other markers, which allows the captured cells to be used for further testing.

Based on the reported figures, the contract value equates to roughly US$650 per sample (US$65,000 divided by about 100 samples). This is a simple average and not a pricing figure disclosed by the company.

CelLBxHealth has sites in Guildford in the UK and Plymouth Meeting in the US. The announcement did not say which site will carry out the work.

What management said

Executive Chairman Dr Jan Groen said: "We are pleased to expand our relationship with our established US pharmaceutical partner." He added that the agreement "demonstrates the value of Parsortix in enabling advanced molecular analysis."

Dr Groen also said he expects "repeat business opportunities" and "sustainable revenue growth". These are management expectations, and the announcement did not quantify them or provide revenue guidance.

Context and what to watch next

The contract is small in absolute terms, and the announcement does not compare it with the company's revenue or order book. Its significance lies mainly in the fact that it is repeat work from an existing customer under an established framework agreement, and that it involves using Parsortix to supply cells for molecular analysis rather than for cell counting alone.

Points to watch include whether the partner issues further SOWs under the same Master Services Agreement, as management has suggested it hopes, and whether CelLBxHealth (LSE:CLBX) discloses additional pharmaceutical services work using the platform. The timing of revenue recognition on this SOW was not specified.